Melatonin exerts an antidepressant-like effect in the tail suspension test in mice: evidence for involvement of N-methyl-d-aspartate receptors and the l-arginine-nitric oxide pathway

Mantovani, M.; Pértile, Renata Aparecida Nedel; Calixto, João B.; Santos, Adair R.S.; Rodrigues, Ana Lúcia S.

doi:10.1016/s0304-3940(03)00306-9

Cited by 169 publications

(111 citation statements)

References 19 publications

Supporting

Mentioning

101

Contrasting

Order By: Relevance

“…Melatonin has induced antidepressant-like effects in the tail suspension [28] and chronic mild stress [31] models but not in the learned helplessness model [24] . In the forced swimming model, repeated [29,33] but not single [25] administration of melatonin exerted antidepressant-like activities.…”

Section: Discussionmentioning

confidence: 94%

“…Melatonin has been used successfully in treating insomnia [20] www.nature.com/aps Tian SW et al Acta Pharmacologica Sinica npg and various circadian rhythm disorders such as delayed sleep phase syndrome [21] and shift-work sleep disorder [22] . Melatonin and its agonists exert antidepressant-and/or anxiolytic effects in animal models [23][24][25][26][27][28][29][30][31][32][33][34] . Clinical administration of melatonin or melatonin agonists has been effective in improving depressive symptoms [35,36] .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Antidepressant- and anxiolytic effects of the novel melatonin agonist Neu-P11 in rodent models

et al. 2010

View full text Add to dashboard Cite

Aim: To investigate the potential antidepressant and anxiolytic effects of Neu-P11, a novel melatonin agonist, in two models of depression in rats and a model of anxiety in mice. Methods: In the learned helplessness test (LH), Neu-P11 or melatonin (25-100 mg/kg, ip) was administered to rats 2 h before the beginning of the dark phase once a day for 5 days and the number of escape failures and intertrial crossings during the test phase were recorded. In the forced swimming test (FST), rats received a single or repeated administration of Neu-P11 (25-100 mg/kg, ip). The total period of immobility during the test phase was assessed. In the elevated plus-maze test (EPM), mice were treated with Neu-P11 (25-100 mg/kg, ip) or melatonin in the morning or in the evening and tested 2 h later. The percentage of time spent in the open arms and the open arms entries were assessed. Results: In the LH test, Neu-P11 but not melatonin significantly decreased the escape deficit and had no effect on the intertrial crossings. In the FST, a single or repeated administration of Neu-P11, either in the morning or in the evening, significantly decreased the duration of immobility. In the EPM test, Neu-P11 significantly increased the percentage of time spent in the open arms and the open arms entries irrespective to the time of administration. Melatonin was effective only when administered in the afternoon. Conclusion:The results demonstrate that Neu-P11 exerts antidepressant and anxiolytic activities in rodent models.

show abstract

Section: Discussionmentioning

confidence: 94%

Section: Introductionmentioning

confidence: 99%

Antidepressant- and anxiolytic effects of the novel melatonin agonist Neu-P11 in rodent models

et al. 2010

View full text Add to dashboard Cite

show abstract

“…Preclinical data has revealed that exogenous melatonin is active in routinely used screening tests for antidepressant actions, such as the forced swim test (FST) (Bourin et al, 2004;Brotto et al, 2000;Ergün et al, 2008;Micale et al, 2006;Overstreet et al, 1998;Raghavendra et al, 2000;Shaji et al, 1998;Ramírez-Rodríguez et al, 2014;Zahra et al, 2012;) and the tail suspension test (TST) (Prakhie et al, 1998;Mantovani et al, 2003;Binfarè et al, 2010;Oxenkrug et al, 2010) (Table 2). Agomelatine was reported to be more efficacious than melatonin in the FST on naïve rats and mice (Bourin et al, 2004) as well as on transgenic mice with low glucocorticoid receptor (GR) function (Barden et al, 2005).…”

Section: Melatonin and Depressionmentioning

confidence: 99%

The role of the melatoninergic system in epilepsy and comorbid psychiatric disorders

Tchekalarova

Moyanova

Fusco

et al. 2015

Brain Research Bulletin

View full text Add to dashboard Cite

Abstract\ud \ud There is emerging evidence of the beneficial role of the melatonin system in a wide range of psychiatric and neurologic disorders, including anxiety, depression, and epilepsy. Although melatoninergic drugs have chronobiotic and antioxidant properties that positively influence circadian rhythm desynchronization and neuroprotection in neurodegenerative disorders, studies examining the use of melatonin for epilepsy's comorbid psychiatric and neurological symptomatology are still limited. Preclinical and clinical findings on the beneficial effects of the melatonin system on anxiety, depression, and epilepsy suggest that melatoninergic compounds might be effective in treating comorbid behavioral complications in epilepsy beyond regulation of a disturbed sleep-wake cycle

show abstract

“…Moreover, some psychopharmacological effects like sedative, antiepileptic and anti-anxiety effects have been proposed for melatonin (Geoffriau et al, 1998) . It has been found in some behavioral studies that melatonin has a prolonged and severe antinociceptive effect in neuropathic pains via interaction with opioidergic and GABAergic system receptors (Golombek et al, 1996;Mantovani et al, 2003) . Although, several studies have mentioned melatonin role in the treatment of neuropathy due to diabetes (Negi et al, 2010;Srinivasan et al, 2010;Arreola-Espino et al, 2007) , there are few studies about its effect on prevention of diabetic neuropathy.…”

Section: Introductionmentioning

confidence: 99%

Effects of Melatonin in Prevention of Neuropathy in STZ-Induced Diabetic Rats

Zangiabadi¹,

Sheibani²,

Asadi-Shekaari³

et al. 2011

American Journal of Pharmacology and Toxicology

View full text Add to dashboard Cite

Problem statement: Diabetes mellitus occurs mainly with chronic polyneuropathy, and oxidative stress plays an important role in emergence of most neurologic and behavioral changes in diabetic patients. Many studies have focused on the beneficial effects of various antioxidants such as melatonin on diabetic neuropathy. The aim of this study is to evaluate the effect of melatonin in prevention of neuropathy in Streptozotocin-induced diabetic rats. After prescribing Streptozotocin (STZ), treatment rats received melatonin (10 mg kg day −1 ) or DMSO for a period of 6 weeks. Approach: At the end of the sixth week, non diabetic control group, diabetic control group (sham) and treated rats were examined by thermal pain response tests (hot plate and tail flick). The horizontal and vertical activities of rats were measured in an open field test. After that, Motor Nerve Conduction Velocity (MNCV) of sciatic-tibial nerve recorded. Also, to study morphological alterations resulting from diabetic neuropathy of sciatic nerve, Myelinated Fiber Diameter (MFD), Axon Diameter (AD) and Myelin Sheath Diameter (MSD) were evaluated by light microscope. Results: According to hot plate results, response time to thermal pain at the end of sixth week in sham group showed a significant decrease in comparison with the control group (p<0.01). In hot plate test, although melatonin approximated to the response time to control group, the significant difference was not observed among melatonin receivers and other groups. In the open field test, Total Distance Moved (TDM) and mobility duration showed significant decrease in sham and DMSO groups in comparison to the control and melatonin groups. Diabetic rats treated with melatonin showed significant increase in MNCV compared to sham and DMSO groups (p<0.05). In morphological study, pretreatment with Melatonin significantly reversed sciatic nerve diameters (MFD, AD, and MSD) reduction in diabetic rats. Electron microscopy showed myelin splitting and myelin sheath infolding in diabetic control group compare to non diabetic group. Conclusion: This study showed that melatonin can decrease the destructive progress of diabetes and causes neuroprotection against damages resulting from STZinduced hyperglycemia.

show abstract

Melatonin exerts an antidepressant-like effect in the tail suspension test in mice: evidence for involvement of N-methyl-d-aspartate receptors and the l-arginine-nitric oxide pathway

Cited by 169 publications

References 19 publications

Antidepressant- and anxiolytic effects of the novel melatonin agonist Neu-P11 in rodent models

Antidepressant- and anxiolytic effects of the novel melatonin agonist Neu-P11 in rodent models

The role of the melatoninergic system in epilepsy and comorbid psychiatric disorders

Effects of Melatonin in Prevention of Neuropathy in STZ-Induced Diabetic Rats

Contact Info

Product

Resources

About